Latest news on drug policy issues in the international media


  • Drugs: researchers shouldn’t just focus on the harms

    Most research is preoccupied with problematic drug use, ignoring the fact that most people who use drugs don’t develop problems
    The Conversation (UK)
    Thursday, February 14, 2019

    Most drug research focuses on the harms they cause, but studying the pleasure they provide will improve our understanding of why people use them. Among other things, this knowledge could be used to help people who develop drug problems, such as dependency. These people have often experienced significant trauma in their lives and use drugs to self-medicate. If we knew more about how this self-medication worked, we could radically transform our approach to treatment. By concentrating research funding on problems people develop rather than investigating motives and benefits of drug use, research has contributed to a distorted view of drugs and the people that use them.

  • Cannabis smoking in teenage years linked to adulthood depression

    Study finds one in 14 cases in under-35s could be avoided if teenagers did not use the drug
    The Guardian (UK)
    Wednesday, February 13, 2019

    Scientists believe they have identified about 60,000 cases of depression in adults under 35 in the UK, and more than 400,000 in the US, that could be avoided if adolescents did not smoke cannabis. An international team of scientists looked at 11 studies published from the mid-1990s onwards, involving a total of more than 23,000 people, they report in the journal JAMA Psychiatry. They explored the use of cannabis for non-medicinal purposes in under-18s. Participants were then followed into adulthood to see who developed clinical depression, anxiety or suicidal behaviour. No single study looked at all three mental health issues. (See also: Teenage cannabis use linked to depression in later life)

  • European Parliament passes cannabis resolution, joins WHO in supporting medical marijuana

    While non-binding, the resolution seeks to incentivize European nations to increase access to medical marijuana
    Forbes (US)
    Wednesday, February 13, 2019

    Following reports about the World Health Organization (WHO) recommending a rescheduling of cannabis and several of its key components under international drug treaties, the European Parliament voted on a resolution that would help advance medical cannabis in the countries that form the European Union. While non-binding, the resolution seeks to incentivize European nations to increase access to medical marijuana, prioritizing scientific research and clinical studies. Same as the WHO’s recommendation, the European Parliament’s resolution shows how wide support for cannabis legalization is, but does not change any actual laws on the international or local levels.

  • The cannabis black market will control 71 per cent of sales in Canada this year, Scotiabank says

    Lack of consistent supply in legal cannabis shops has been a major market stimulator for the illicit sector
    Montreal Gazette (Canada)
    Wednesday, February 13, 2019

    A new research note from Scotiabank analysts estimate that the black market will control 71 percent of cannabis sales in Canada in 2019. The logistical challenges and related supply issued of producing legal cannabis are many–and as a result, the cannabis black market is booming. Oliver Rowe and Ben Isaacson calculated the figure, which reduced its legal recreational sales prediction to about 30 percent, citing supply issues, government inspections, packaging snags and quality control issues as some of the reasons for the low percentage. “As we expect these issues, particularly the limited retail presence in key provinces, to continue through 2019, we have reduced those volumes by 100 metric tonnes, or 30 percent of legal demand,” according to Scotiabank.

  • Slowing the legal weed freight train

    A decriminalization crusader sees a different future for recreational marijuana
    Crain's (US)
    Tuesday, February 12, 2019

    Sabet's strategy for sabotaging legalization is to offer legislators what he calls "a true decriminalization and [social] justice" bill, which would do away with arrests for low-level offenses and replace them with a system for referrals and drug counseling. His idea of replacing arrests with warnings, citations and small fines is a far cry, however, from what most drug reformers have in mind. Although he says SAM is still formulating its approach and aims for flexibility, the recommendations in the "model legislation" on the group's website read almost like a parody of bureaucratic overreach. Many of SAM's purported goals, such as avoiding the overt commercialization of marijuana, could be achieved through legislation, prohibition's opponents say.

  • What is required for Jamaica to export its hi-grade ganja

    Even with legislation in place governing the trade of cannabis, Jamaica’s manufacturing standards must match those of the importing nation
    The Gleaner (Jamaica)
    Monday, February 11, 2019

    Jamaica’s decriminalisation of ganja in 2015 brought with it many expectations, one being the ability to export its hi-grade herb. With a relatively small marketplace (a 2016-2017 Jamaica Health and Lifestyle Survey says 17 per cent of Jamaicans use ganja), investors are eager to expand their market base beyond Jamaica’s 2.9 million citizens. Given Jamaica’s ideal growing conditions and its reputation for producing high-quality varieties, with potentially unique medicinal applications, a licensed producer would have a field of endless opportunities if it developed an international market for its strain. Intellectual property rights protecting that strain would also allow the producer to maximise its earning potential.

  • Cannabis co-ops seek to bring small producers, processors into legal market

    Entering the legal market is too costly and the regulations are too complex
    CBC News (Canada)
    Sunday, February 10, 2019

    British Columbia may be famous for its bud but some say Canada's new marijuana legalization framework is excluding the small producers with established know-how. A movement is growing in the province to address that problem with a common idea: cannabis co-operatives. "Some may argue we've lost our place to either Ontario or Alberta based on the number of licensed producers based out of those provinces," said Barinder Rasode, CEO and co-founder or Grow Tech Labs, a cannabis business accelerator. Grow Tech Labs and Victory Square Technologies launched a cannabis co-op this month that will begin with a provincewide consultation of small producers and processors, Rasode said.

  • Israel approves compassionate use of MDMA to treat PTSD

    Party drug or breakthrough treatment?
    Haaretz (Israel)
    Sunday, February 10, 2019

    MDMA, popularly known as ecstasy, is a drug more commonly associated with raves and nightclubs than a therapist's office. Emerging research has shown promising results in using this "party drug" to treat patients suffering from post-traumatic stress disorder, and Israel's Health Ministry has just approved the use of MDMA to treat dozens of patients. MDMA is classified in Israel as a "dangerous drug", recreational use is illegal, and therapeutic use of MDMA has yet to be formally approved and is still in clinical trials. However, this treatment is deemed as "compassionate use," which allows drugs that are still in development to be made available to patients outside of a clinical trial due to the lack of effective alternatives.

  • WHO recommends rescheduling cannabis in international law for first time in history

    The WHO Expert Committee on Drug Dependence has recommended that cannabis resin and other marijuana products should be removed from a schedule IV
    Newsweek (US)
    Friday, February 8, 2019

    The World Health Organization has suggested that cannabis should be removed from Schedule IV of the 1961 UN Single Convention given the mounting evidence showing that the drug could prove beneficial in treating a number of health problems. International drug policy expert Martin Jelsma from the Transnational Institute said this was the “first time in history” that the WHO had undertaken a proper critical review of cannabis and related substances. Nevertheless, he said the committee’s proposals don’t go far enough, noting that its rationale for keeping cannabis in schedule I is “highly questionable.”

  • Safe injection site for opioid users faces Trump administration crackdown

    San Francisco, New York, Seattle, Denver and Boston have also seriously considered safe injection sites
    The New York Times (US)
    Wednesday, February 6, 2019

    The Justice Department is suing to stop a Philadelphia group from opening what some public health experts and mayors consider the next front in fighting the opioid epidemic: a place where people who inject fentanyl and other illicit drugs can do so under medical supervision.The nonprofit group, Safehouse, was formed last year to house the country’s first so-called safe injection site in Philadelphia, which has one of the nation’s highest rates of overdose deaths. Safehouse had been planning to open the site as soon as next month. But the Justice Department says it would “normalize” the use of deadly drugs.

Page 7 of 339